Traders Buy Large Volume of Edwards Lifesciences Call Options (NYSE:EW)

Edwards Lifesciences Co. (NYSE:EW) saw some unusual options trading on Friday. Stock traders acquired 30,930 call options on the stock. This represents an increase of 251% compared to the typical daily volume of 8,811 call options.

Insider Activity

In other news, VP Donald E. Bobo, Jr. sold 5,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total value of $330,400.00. Following the transaction, the vice president now directly owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 5,000 shares of the company’s stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $66.08, for a total transaction of $330,400.00. Following the transaction, the vice president now owns 46,936 shares of the company’s stock, valued at approximately $3,101,530.88. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction on Tuesday, August 20th. The stock was sold at an average price of $69.95, for a total value of $87,437.50. Following the transaction, the vice president now directly owns 29,333 shares in the company, valued at approximately $2,051,843.35. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 16,250 shares of company stock worth $1,218,138. Company insiders own 1.29% of the company’s stock.

Institutional Trading of Edwards Lifesciences

Large investors have recently added to or reduced their stakes in the stock. 9258 Wealth Management LLC grew its stake in Edwards Lifesciences by 24.8% during the fourth quarter. 9258 Wealth Management LLC now owns 10,529 shares of the medical research company’s stock valued at $803,000 after acquiring an additional 2,093 shares in the last quarter. Gryphon Financial Partners LLC grew its stake in Edwards Lifesciences by 35.7% during the fourth quarter. Gryphon Financial Partners LLC now owns 6,454 shares of the medical research company’s stock valued at $492,000 after acquiring an additional 1,698 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Edwards Lifesciences by 5.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,172,836 shares of the medical research company’s stock valued at $89,433,000 after acquiring an additional 58,442 shares in the last quarter. M&G Investment Management Ltd. grew its stake in Edwards Lifesciences by 10.8% during the fourth quarter. M&G Investment Management Ltd. now owns 8,826 shares of the medical research company’s stock valued at $671,000 after acquiring an additional 863 shares in the last quarter. Finally, Janney Montgomery Scott LLC grew its stake in Edwards Lifesciences by 2.9% during the fourth quarter. Janney Montgomery Scott LLC now owns 76,614 shares of the medical research company’s stock valued at $5,842,000 after acquiring an additional 2,126 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analysts Set New Price Targets

EW has been the topic of a number of recent analyst reports. Baird R W cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 25th. Wells Fargo & Company lowered their target price on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday. The Goldman Sachs Group lowered their target price on Edwards Lifesciences from $107.00 to $91.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Barclays lowered their target price on Edwards Lifesciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research note on Monday. Finally, Truist Financial lowered their target price on Edwards Lifesciences from $82.00 to $71.00 and set a “hold” rating for the company in a research note on Friday. Fifteen equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $80.29.

Edwards Lifesciences Trading Up 2.5 %

NYSE EW traded up $1.73 on Friday, hitting $69.86. The company’s stock had a trading volume of 5,257,601 shares, compared to its average volume of 4,218,784. The company has a quick ratio of 2.87, a current ratio of 3.71 and a debt-to-equity ratio of 0.08. Edwards Lifesciences has a 1-year low of $58.93 and a 1-year high of $96.12. The company’s 50-day moving average is $72.86 and its 200 day moving average is $83.61. The firm has a market cap of $42.08 billion, a PE ratio of 30.23, a PEG ratio of 2.85 and a beta of 1.13.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Wednesday, July 24th. The medical research company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.69 by $0.01. Edwards Lifesciences had a net margin of 24.55% and a return on equity of 22.35%. The business had revenue of $1.63 billion for the quarter, compared to analyst estimates of $1.65 billion. During the same period in the prior year, the firm earned $0.66 earnings per share. Edwards Lifesciences’s revenue was up 6.7% on a year-over-year basis. As a group, analysts predict that Edwards Lifesciences will post 2.7 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.